Muyue Yang, Zhen Yang, Pu Wang, Zhihui Sun
Photobiomodulation using light in the red or near-infrared region is an innovative treatment strategy for a wide range of neurological and psychological conditions. Photobiomodulation can promote neurogenesis and elicit anti-apoptotic, anti-inflammatory and antioxidative responses. Its therapeutic effects have been demonstrated in studies on neurological diseases, peripheral nerve injuries, pain relief and wound healing. We conducted a comprehensive literature review of the application of photobiomodulation in patients with central nervous system diseases in February 2019...
June 2021: Neural Regeneration Research
Hiba Kazmi, Zuzana Walker, Jan Booij, Faraan Khan, Sachit Shah, Carole H Sudre, Joshua E J Buckman, Anette-Eleonore Schrag
BACKGROUND: Late onset depression (LOD) may precede the diagnosis of Parkinson's disease (PD) or dementia with Lewy bodies (DLB). We aimed to determine the rate of clinical and imaging features associated with prodromal PD/DLB in patients with LOD. METHODS: In a cross-sectional design, 36 patients with first onset of a depressive disorder (Diagnostic and Statistical Manual of Mental Disorders IV criteria) diagnosed after the age of 55 (LOD group) and 30 healthy controls (HC) underwent a detailed clinical assessment...
February 2021: Journal of Neurology, Neurosurgery, and Psychiatry
Roxanne Lofredi, Wolf-Julian Neumann, Antje Bock, Andreas Horn, Julius Huebl, Sandy Siegert, Gerd-Helge Schneider, Joachim K Krauss, Andrea A Kühn
Gamma synchronization increases during movement and scales with kinematic parameters. Here, disease-specific characteristics of this synchronization and the dopamine-dependence of its scaling in Parkinson's disease are investigated. In 16 patients undergoing deep brain stimulation surgery, movements of different velocities revealed that subthalamic gamma power peaked in the sensorimotor part of the subthalamic nucleus, correlated positively with maximal velocity and negatively with symptom severity. These effects relied on movement-related bursts of transient synchrony in the gamma band...
February 1, 2018: ELife
Abdullah Mosabbir, Quincy J Almeida, Heidi Ahonen
Recent studies have suggested that vibration therapy may have a positive influence in treating motor symptoms of Parkinson's disease (PD). However, quantitative evidence of the benefits of vibration utilized inconsistent methods of vibration delivery, and to date there have been no studies showing a long-term benefit of 40 Hz vibration in the PD population. The objective of this study was to demonstrate the efficacy of vibration administered via a physioacoustic therapy method (PAT) on motor symptoms of PD over a longer term, completed as a randomized placebo-controlled trial...
April 28, 2020: Healthcare (Basel, Switzerland)
Aurelie Schwartzentruber, Camilla Boschian, Fernanda Martins Lopes, Monika A Myszczynska, Elizabeth J New, Julien Beyrath, Jan Smeitink, Laura Ferraiuolo, Heather Mortiboys
Mutations in PRKN are the most common cause of early onset Parkinson's disease. Parkin is an E3 ubiquitin ligase, functioning in mitophagy. Mitochondrial abnormalities are present in PRKN mutant models. Patient derived neurons are a promising model in which to study pathogenic mechanisms and therapeutic targets. Here we generate induced neuronal progenitor cells from PRKN mutant patient fibroblasts with a high dopaminergic neuron yield. We reveal changing mitochondrial phenotypes as neurons undergo a metabolic switch during differentiation...
September 23, 2020: Scientific Reports
Chieh-Sen Chuang, Jui-Chih Chang, Fu-Chou Cheng, Ko-Hung Liu, Hong-Lin Su, Chin-San Liu
PURPOSE: Parkinson's disease (PD) is a progressive degenerative central nervous system disorder that particularly impairs motor function. As PD advances, gait disorders become more pronounced and are often difficult to treat with current pharmacological therapies. Physical activity improves both mobility in and the daily living activities of patients with PD. Mitochondrial alterations and oxidative stress contribute to PD progression. Therefore, the association between mitochondria and exercise in PD and the implicated regulation of mitochondrial proteins was explored in this study...
December 15, 2017: Life Sciences
Aaron Song Chuan Foo, Tuck Wah Soong, Tseng Tsai Yeo, Kah-Leong Lim
As the main driver of energy production in eukaryotes, mitochondria are invariably implicated in disorders of cellular bioenergetics. Given that dopaminergic neurons affected in Parkinson's disease (PD) are particularly susceptible to energy fluctuations by their high basal energy demand, it is not surprising to note that mitochondrial dysfunction has emerged as a compelling candidate underlying PD. A recent approach towards forestalling dopaminergic neurodegeneration in PD involves near-infrared (NIR) photobiomodulation (PBM), which is thought to enhance mitochondrial function of stimulated cells through augmenting the activity of cytochrome C oxidase...
2020: Frontiers in Aging Neuroscience
John Mitrofanis, Luke A Henderson
No abstract text is available yet for this article.
December 2020: Neural Regeneration Research
Joseph Jankovic, Eng King Tan
The concept of 'idiopathic' Parkinson's disease (PD) as a single entity has been challenged with the identification of several clinical subtypes, pathogenic genes and putative causative environmental agents. In addition to classic motor symptoms, non-motor manifestations (such as rapid eye movement sleep disorder, anosmia, constipation and depression) appear at prodromic/premotor stage and evolve, along with cognitive impairment and dysautonomia, as the disease progresses, often dominating the advanced stages of the disease...
August 2020: Journal of Neurology, Neurosurgery, and Psychiatry
Rubén Fernández-Santiago, Alex Iranzo, Carles Gaig, Mónica Serradell, Manel Fernández, Eduardo Tolosa, Joan Santamaría, Mario Ezquerra
Recently, we reported downregulated circulating levels of the microRNAs miR-19b, miR-29a, and miR-29c in Parkinson disease. Here we investigated the expression of these microRNAs in serum samples from 56 patients with idiopathic rapid eye movement sleep behavior disorder, before and after their conversion into a synucleinopathy. Compared to controls, we found that the expression level of miR-19b is downregulated in patients with idiopathic rapid eye movement sleep behavior disorder and antedates the diagnosis of Parkinson disease and dementia with Lewy bodies after 4...
May 2015: Annals of Neurology
Lynne Krohn, Richard Y J Wu, Karl Heilbron, Jennifer A Ruskey, Sandra B Laurent, Cornelis Blauwendraat, Armaghan Alam, Isabelle Arnulf, Michele T M Hu, Yves Dauvilliers, Birgit Högl, Mathias Toft, Kari Anne Bjørnarå, Ambra Stefani, Evi Holzknecht, Christelle Charley Monaca, Beatriz Abril, Giuseppe Plazzi, Elena Antelmi, Luigi Ferini-Strambi, Peter Young, Anna Heidbreder, Valérie Cochen De Cock, Brit Mollenhauer, Friederike Sixel-Döring, Claudia Trenkwalder, Karel Sonka, David Kemlink, Michela Figorilli, Monica Puligheddu, Femke Dijkstra, Mineke Viaene, Wolfang Oertel, Marco Toffoli, Gian Luigi Gigli, Mariarosaria Valente, Jean-François Gagnon, Mike A Nalls, Andrew B Singleton, Alex Desautels, Jacques Y Montplaisir, Paul Cannon, Owen A Ross, Bradley F Boeve, Nicolas Dupré, Edward A Fon, Ronald B Postuma, Lasse Pihlstrøm, Guy A Rouleau, Ziv Gan-Or
OBJECTIVE: Rapid eye movement sleep behavior disorder (RBD) is a prodromal synucleinopathy, as >80% will eventually convert to overt synucleinopathy. We performed an in-depth analysis of the SNCA locus to identify RBD-specific risk variants. METHODS: Full sequencing and genotyping of SNCA was performed in isolated/idiopathic RBD (iRBD, n = 1,076), Parkinson disease (PD, n = 1,013), dementia with Lewy bodies (DLB, n = 415), and control subjects (n = 6,155). The iRBD cases were diagnosed with RBD prior to neurodegeneration, although some have since converted...
April 2020: Annals of Neurology
Alex Iranzo, Joan Santamaria, Eduardo Tolosa
Idiopathic rapid eye movement (REM) sleep behaviour disorder (IRBD) manifests as unpleasant dreams and vigorous behaviours during REM sleep that can result in injuries. Patients with IRBD have no known neurological diseases or motor or cognitive complaints; however, this sleep disorder is not harmless. In most cases, IRBD is the prelude of the synucleinopathies Parkinson's disease, dementia with Lewy bodies, or, less frequently, multiple system atrophy. Patients can show abnormalities that are characteristic of the synucleinopathies, and longitudinal follow-up shows that most patients develop parkinsonism and cognitive impairments with time...
April 2016: Lancet Neurology
Hao Qian, Xinjiang Kang, Jing Hu, Dongyang Zhang, Zhengyu Liang, Fan Meng, Xuan Zhang, Yuanchao Xue, Roy Maimon, Steven F Dowdy, Neal K Devaraj, Zhuan Zhou, William C Mobley, Don W Cleveland, Xiang-Dong Fu
Parkinson's disease is characterized by loss of dopamine neurons in the substantia nigra1 . Similar to other major neurodegenerative disorders, there are no disease-modifying treatments for Parkinson's disease. While most treatment strategies aim to prevent neuronal loss or protect vulnerable neuronal circuits, a potential alternative is to replace lost neurons to reconstruct disrupted circuits2 . Here we report an efficient one-step conversion of isolated mouse and human astrocytes to functional neurons by depleting the RNA-binding protein PTB (also known as PTBP1)...
June 2020: Nature
M Bourdenx, A Nioche, S Dovero, M-L Arotcarena, S Camus, G Porras, M-L Thiolat, N P Rougier, A Prigent, P Aubert, S Bohic, C Sandt, F Laferrière, E Doudnikoff, N Kruse, B Mollenhauer, S Novello, M Morari, T Leste-Lasserre, I Trigo Damas, M Goillandeau, C Perier, C Estrada, N Garcia-Carrillo, A Recasens, N N Vaikath, O M A El-Agnaf, M T Herrero, P Derkinderen, M Vila, J A Obeso, B Dehay, E Bezard
Dopaminergic neuronal cell death, associated with intracellular α-synuclein (α-syn)-rich protein aggregates [termed "Lewy bodies" (LBs)], is a well-established characteristic of Parkinson's disease (PD). Much evidence, accumulated from multiple experimental models, has suggested that α-syn plays a role in PD pathogenesis, not only as a trigger of pathology but also as a mediator of disease progression through pathological spreading. Here, we have used a machine learning-based approach to identify unique signatures of neurodegeneration in monkeys induced by distinct α-syn pathogenic structures derived from patients with PD...
May 2020: Science Advances
Marie-Laure Arotcarena, Sandra Dovero, Alice Prigent, Mathieu Bourdenx, Sandrine Camus, Gregory Porras, Marie-Laure Thiolat, Maddalena Tasselli, Philippe Aubert, Niels Kruse, Brit Mollenhauer, Ines Trigo Damas, Cristina Estrada, Nuria Garcia-Carrillo, Nishant N Vaikath, Omar M A El-Agnaf, Maria Trinidad Herrero, Miquel Vila, Jose A Obeso, Pascal Derkinderen, Benjamin Dehay, Erwan Bezard
In Parkinson's disease, synucleinopathy is hypothesized to spread from the enteric nervous system, via the vagus nerve, to the CNS. Here, we compare, in baboon monkeys, the pathological consequences of either intrastriatal or enteric injection of α-synuclein-containing Lewy body extracts from patients with Parkinson's disease. This study shows that patient-derived α-synuclein aggregates are able to induce nigrostriatal lesions and enteric nervous system pathology after either enteric or striatal injection in a non-human primate model...
May 1, 2020: Brain
Farzad Salehpour, Michael R Hamblin
Photobiomodulation (PBM) might be an effective treatment for Parkinson's disease (PD) in human patients. PBM of the brain uses red or near infrared light delivered from a laser or an LED at relatively low power densities, onto the head (or other body parts) to stimulate the brain and prevent degeneration of neurons. PD is a progressive neurodegenerative disease involving the loss of dopamine-producing neurons in the substantia nigra deep within the brain. PD is a movement disorder that also shows various other symptoms affecting the brain and other organs...
April 15, 2020: Biomolecules
Kathy Dujardin, Véronique Sgambato
Besides the hallmark motor symptoms (rest tremor, hypokinesia, rigidity, and postural instability), patients with Parkinson's disease (PD) have non-motor symptoms, namely neuropsychiatric disorders. They are frequent and may influence the other symptoms of the disease. They have also a negative impact on the quality of life of patients and their caregivers. In this article, we will describe the clinical manifestations of the main PD-related behavioral disorders (depression, anxiety disorders, apathy, psychosis, and impulse control disorders)...
2020: Frontiers in Neuroscience
José Alexandre S Crippa, Jaime E C Hallak, Antônio W Zuardi, Francisco S Guimarães, Vitor Tumas, Rafael G Dos Santos
Parkinson's disease (PD) is a chronic neurodegenerative disorder characterized by motor symptoms such as bradykinesia, rest tremor, postural disturbances, and rigidity. PD is also characterized by non-motor symptoms such as sleep disturbances, cognitive deficits, and psychiatric disorders such as psychosis, depression, and anxiety. The pharmacological treatment for these symptoms is limited in efficacy and induce significant adverse reactions, highlighting the need for better treatment options. Cannabidiol (CBD) is a phytocannabinoid devoid of the euphoriant and cognitive effects of tetrahydrocannabinol, and preclinical and preliminary clinical studies suggest that this compound has therapeutic effect in non-motor symptoms of PD...
February 2019: European Archives of Psychiatry and Clinical Neuroscience
Andrea Beatriz Cragnolini, Giorgia Lampitella, Assunta Virtuoso, Immacolata Viscovo, Fivos Panetsos, Michele Papa, Giovanni Cirillo
The main pathological feature of the neurodegenerative diseases is represented by neuronal death that represents the final step of a cascade of adverse/hostile events. Early in the neurodegenerative process, glial cells (including astrocytes, microglial cells, and oligodendrocytes) activate and trigger an insidious neuroinflammatory reaction, metabolic decay, blood brain barrier dysfunction and energy impairment, boosting neuronal death. How these mechanisms might induce selective neuronal death in specific brain areas are far from being elucidated...
May 2020: Neural Regeneration Research
Olga Corti, Klas Blomgren, Anglo Poletti, Philip M Beart
In autophagy long-lived proteins, protein aggregates or damaged organelles are engulfed by vesicles called autophagosomes prior to lysosomal degradation. Autophagy dysfunction is a hallmark of several neurodegenerative diseases in which misfolded proteins or dysfunctional mitochondria accumulate. Excessive autophagy can also exacerbate brain injury under certain conditions. In this review, we provide specific examples to illustrate the critical role played by autophagy in pathological conditions affecting the brain and discuss potential therapeutic implications...
March 9, 2020: Journal of Neurochemistry
2020-03-15 10:20:05
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"